Ets1 as a marker of malignant potential in gastric carcinoma.

AIM Ets1 proto-oncogene is a transcription factor involved in the activation of several genes of tumor invasion and metastasis. We aimed to determine the relationship between the extent and intensity of Ets1 expression and patients' clinicopathological factors in gastric carcinoma. METHODS Immunohistochemical analysis was performed for gastric tumor paraffin-embedded sections, followed by image analysis. RESULTS Ets1 was not expressed in the normal gastric epithelium and its surrounding cells. The percentage of Ets1 expressing cells detected increased significantly in both epithelial tumor and stromal cells from high T classification, lymph node metastasis positive, clinical advanced-stage groups (P<0.001). The level of Ets1 staining in epithelial tumor cells also reflected the degree of cell differentiation. The percentage of epithelial and stromal cells expressing Ets1 was significantly correlated with the presence of lymph node metastasis (P=0.014 and P<0.001 respectively). Ets1 expression was not observed in tissue samples from patients with benign gastric ulcers. CONCLUSION Ets1 protein expression in epithelial tumor cells reflects the degree of differentiation, and the percentage of Ets1 positive tumor and stromal cells correlates with lymph node metastasis. Thus Ets1 is a valuable marker of malignant potential in terms of invasiveness and metastasis of gastric carcinoma. It is also possible that inhibition of Ets1 is a potential avenue for therapy in gastric cancer.

[1]  Y. Okada,et al.  Ets-1 positively regulates expression of urokinase-type plasminogen activator (uPA) and invasiveness of astrocytic tumors. , 1999, Journal of neuropathology and experimental neurology.

[2]  K. Shirato,et al.  Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. , 2001, Biochemical and biophysical research communications.

[3]  E. Tahara.  Molecular aspects of invasion and metastasis of stomach cancer. , 2000, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[4]  J. Gusella,et al.  A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. , 1998, Cancer research.

[5]  M. Tymms,et al.  The Ets1 transcription factor is widely expressed during murine embryo development and is associated with mesodermal cells involved in morphogenetic processes such as organ formation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Sweep,et al.  Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer , 2002, Oncogene.

[7]  Z. Liu,et al.  Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors , 2003, Thorax.

[8]  R. Muise-Helmericks,et al.  Signal transduction and the Ets family of transcription factors , 2000, Oncogene.

[9]  J. Ajani,et al.  Adjuvant therapy for gastric carcinoma patients in the past 15 years , 1999, Cancer.

[10]  M. Abe,et al.  Role of Transcription Factors in Angiogenesis , 2001 .

[11]  N. Takai,et al.  Expression of c‐Ets1 is associated with malignant potential in endometrial carcinoma , 2000, Cancer.

[12]  J. Ferlay,et al.  Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18–29 (1999). , 1999, International journal of cancer.

[13]  Marc Aumercier,et al.  ETS-1 Transcription Factor Binds Cooperatively to the Palindromic Head to Head ETS-binding Sites of the Stromelysin-1 Promoter by Counteracting Autoinhibition* , 2002, The Journal of Biological Chemistry.

[14]  H. Sasaki,et al.  Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. , 2001, The Journal of surgical research.

[15]  T. Giordano,et al.  RNAi: gene-silencing in therapeutic intervention. , 2002, Drug discovery today.

[16]  Lars S Jermiin,et al.  A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13–15, a region subject to LOH and rearrangement in human carcinoma cell lines , 1998, Oncogene.

[17]  O. Kallioniemi,et al.  Tissue microarray technology for high-throughput molecular profiling of cancer. , 2001, Human molecular genetics.

[18]  A. Wellmann,et al.  The Ets‐1 transcription factor is up‐regulated together with MMP 1 and MMP 9 in the stroma of pre‐invasive breast cancer , 2001, The Journal of pathology.

[19]  T. Nakayama,et al.  Expression of the ets-1 proto-oncogene in human pancreatic carcinoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[20]  I. Kola,et al.  ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway. , 2003, Human molecular genetics.

[21]  I. Sekine,et al.  Expression of the ets-1 proto-oncogene in human thyroid tumor. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[22]  M. Trojanowska.  Ets factors and regulation of the extracellular matrix , 2000, Oncogene.

[23]  J. Ferlay,et al.  Estimates of the worldwide mortality from 25 cancers in 1990 , 1999, International journal of cancer.

[24]  R. Ralhan,et al.  Coexpression of Ets-1 and p53 in oral carcinomas is associated with P-glycoprotein expression and poor prognosis , 2002, Journal of Cancer Research and Clinical Oncology.

[25]  Paul J Hertzog,et al.  Ets1 is required for p53 transcriptional activity in UV‐induced apoptosis in embryonic stem cells , 2002, The EMBO journal.

[26]  K. Mimori,et al.  Prognostic score of gastric cancer determined by cDNA microarray. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  I. Kola,et al.  Transformation induced by Ewing's sarcoma associated EWS/FLI-1 is suppressed by KRAB/FLI-1 , 2003, British Journal of Cancer.

[28]  Y. Ikeda,et al.  Regulation of the GnT-V Promoter by Transcription Factor Ets-1 in Various Cancer Cell Lines* , 1999, The Journal of Biological Chemistry.

[29]  Zhihua Liu,et al.  Overexpression of ETS2 in human esophageal squamous cell carcinoma. , 2003, World journal of gastroenterology.

[30]  Yusuke Nakamura,et al.  Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. , 2002, Cancer research.

[31]  J. Nesland,et al.  Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  Sang-Oh Yoon,et al.  Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. , 2003, Journal of biochemistry and molecular biology.